Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 8;8:734901. doi: 10.3389/fmed.2021.734901

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Kuempers, Jagomast, Krupar, Paulsen, Heidel, Ribbat-Idel, Idel, Märkl, Anlauf, Berezowska, Tiemann, Bösmüller, Fend, Kalsdorf, Bohnet, Dreyer, Sailer, Kirfel and Perner.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Overall survival according to DLL3 expression status. (A) Kaplan–Meier curves stratified according to DLL3-high or DLL3-low status assessed with TPS in chemorelapsed specimens (log-rank p = 0.57). (B) Kaplan–Meier curves stratified according to DLL3-high or DLL3-low status assessed with TPS in chemonaive specimens (log-rank p = 0.42). (C) Kaplan–Meier curves stratified according to dynamics of DLL3 expression in the course of therapy. Persisted DLL3-low was defined as TPS < 50% in chemonaive and chemorelapsed samples, persisted DLL3-high was defined as TPS ≥ 50% in chemonaive and chemorelapsed samples, “up” was defined as a switch from TPS < 50% to ≥ 50%, and “down” was defined as a switch from TPS ≥ 50% to <50% in the course of therapy (log-rank test p = 0.56).